BioNTech Investor Day Presentation Deck

Building on COVID-19 vaccine leadership to address global challenges Advancing a broad toolkit of mRNA vaccines, Ribologicals, Ribolysins Diverse pipeline of next-generation COVID-19 vaccines Delivering breakthroughs against infectious diseases with high need Ability to precisely address diverse and difficult-to-target pathogens New vaccine launches and clinical trial starts expected in 2H 2022 NUM INUT BIONTECH YOUR 60

View entire presentation